8RH2

Trimeric HSV-2G gB ectodomain in postfusion conformation with three bound HDIT102 Fab molecules.

Summary for 8RH2

• Entry DOI: 10.2210/pdb8rh2/pdb
• EMDB information: 19163 19164 19165 19166
• Descriptor: Envelope glycoprotein B, HDIT102 Fab heavy chain, HDIT102 Fab light chain (3 entities in total)
• Functional Keywords: ectodomain, post-fusion, fab molecule, trimeric, viral protein
• Biological source: Human herpesvirus 2 strain G; More
• Total number of polymer chains: 9
• Total formula weight: 453277.17

Authors

Kalbermatter, D.,Seyfizadeh, N.,Imhof, T.,Ries, M.,Mueller, C.,Jenner, L.,Blumenschein, E.,Yendrzheyevskiy, A.,Moog, K.,Eckert, D.,Engel, R.,Diebolder, P.,Chami, M.,Krauss, J.,Schaller, T.,Arndt, M. (deposition date: 2023-12-14, release date: 2024-06-19, Last modification date: 2024-11-13)

Primary citation

Seyfizadeh, N.,Kalbermatter, D.,Imhof, T.,Ries, M.,Muller, C.,Jenner, L.,Blumenschein, E.,Yendrzheyevskiy, A.,Grun, F.,Moog, K.,Eckert, D.,Engel, R.,Diebolder, P.,Chami, M.,Krauss, J.,Schaller, T.,Arndt, M.
Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus.
J.Biomed.Sci., 31:56-56, 2024

PubMed Abstract: Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistant to standard therapies. HDIT101, a humanized IgG targeting HSV-1/2 gB was previously investigated in phase 2 clinical trials. The aim of this study was to develop a next-generation therapy by combining different antiviral monoclonal antibodies.

PubMed: 38807208
DOI: 10.1186/s12929-024-01045-2

Experimental method

ELECTRON MICROSCOPY (3.12 Å)